The earnings call highlighted the successful early stages of Orlynda's launch and positive market feedback, indicating potential for growth. However, financial challenges remain due to limited initial revenue, increased expenses, and the need for additional capital.

Company Guidance

In the third quarter of 2025, Iterum Therapeutics reported net product sales of $400,000 with the launch of Orlynda in the U.S. in August 2025. The company successfully generated over 280 prescriptions through more than 100 unique prescribers, indicating growing physician and patient engagement. Approximately 40% of prescriptions have been filled through payer approval processes, aligning with expectations despite awaiting broader payer coverage. Iterum anticipates 2026 net product revenue to range between $5 million and $15 million, supported by expanding insurance coverage, particularly with a recent signed rebate agreement with a top Medicare Part D pharmacy benefit manager. Operating expenses for 2026 are projected between $25 million and $30 million, with current cash reserves expected to fund operations into 2026. The company aims to raise additional capital to sustain commercialization efforts, targeting high-value territories and potentially expanding further.

Successful Initial Launch of Orlynda

Orlynda was launched on August 20, 2025, and generated more than 280 prescriptions through 100 unique prescribers, with nearly half prescribing to more than one patient.

Positive Physician Feedback

Physicians have shown strong interest in Orlynda as a new treatment option for uncomplicated urinary tract infections, particularly where antibiotic resistance is a challenge.

Advancements in Managed Care and Market Access

Iterum has a signed rebate agreement with a top Medicare Part D pharmacy benefit manager, increasing coverage and access for Orlynda starting in 2026 or 2027.

Patent Expansion

New patents granted in China and Mexico, extending Iterum's intellectual property protection to 2041 and 2039, respectively.

Iterum Therapeutics (ITRM) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

ITRM Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Mar 12, 2026	2025 (Q4)	- / -	-0.12	―	―	―
Nov 14, 2025	2025 (Q3)	-0.09 / -0.16	-0.24	33.33% (+0.08)	―
Aug 05, 2025	2025 (Q2)	-0.11 / -0.13	-0.23	43.48% (+0.10)	―
May 13, 2025	2025 (Q1)	-0.14 / -0.10	-0.38	73.68% (+0.28)	―
Feb 07, 2025	2024 (Q4)	-0.17 / -0.12	-0.81	85.19% (+0.69)	―
Nov 14, 2024	2024 (Q3)	-0.17 / -0.24	-1.2	80.00% (+0.96)	―
Aug 14, 2024	2024 (Q2)	-0.45 / -0.23	-0.77	70.13% (+0.54)	―
May 13, 2024	2024 (Q1)	-0.72 / -0.38	-0.58	34.48% (+0.20)	―
Mar 28, 2024	2023 (Q4)	-0.94 / -0.81	-0.66	-22.73% (-0.15)	―
Nov 14, 2023	2023 (Q3)	-0.88 / -1.20	-0.43	-179.07% (-0.77)	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

ITRM Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Nov 14, 2025	$0.56	$0.47	-16.07%
Aug 05, 2025	$0.71	$0.70	-1.41%
May 13, 2025	$1.01	$0.94	-6.93%
Feb 07, 2025	$1.49	$1.43	-4.03%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Iterum Therapeutics Plc (ITRM) report earnings?

Iterum Therapeutics Plc (ITRM) is schdueled to report earning on Mar 12, 2026, TBA (Confirmed).

What is Iterum Therapeutics Plc (ITRM) earnings time?

Iterum Therapeutics Plc (ITRM) earnings time is at Mar 12, 2026, TBA (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is ITRM EPS forecast?

Currently, no data Available

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing